Page last updated: 2024-08-25

talinolol and digoxin

talinolol has been researched along with digoxin in 14 studies

Research

Studies (14)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's7 (50.00)29.6817
2010's7 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Artursson, P; Neuhoff, S; Ungell, AL; Zamora, I1
Thakker, DR; Troutman, MD1
Collett, A; Hallifax, D; Tanianis-Hughes, J; Warhurst, G1
Lombardo, F; Obach, RS; Waters, NJ1
Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV1
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV1
Franke, G; Giessmann, T; Kroemer, HK; Oertel, R; Siegmund, W; Stuhr, M; Terhaag, B; Weinbrenner, A; Westphal, K; Zschiesche, M1
Chiou, WL; Chung, SM; Ma, C; Wu, TC1
Beale, KK; Bertino, JS; Ma, JD; Nafziger, AN; Trivedi, M; Tsunoda, SM1
Oswald, S; Siegmund, W; Terhaag, B1
Sermsappasuk, P; Siegmund, W; Weiss, M1
Kallem, R; Kulkarni, CP; Mahammad, SS; Mandlekar, S; Patel, D; Singh, SP; Sinz, M; Thakur, M1
Akamine, Y; Uno, T; Yasui-Furukori, N1
Costales, C; Eatemadpour, S; Kimoto, E; Lazzaro, S; Varma, MV; Yamazaki, S1

Reviews

3 review(s) available for talinolol and digoxin

ArticleYear
Evaluation of in vivo P-glycoprotein phenotyping probes: a need for validation.
    Clinical pharmacokinetics, 2010, Volume: 49, Issue:4

    Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Digoxin; Drug Interactions; Genotype; Humans; Pharmacogenetics; Phenotype; Polymorphism, Single Nucleotide; Prescription Drugs; Propanolamines; Quinidine; Reproducibility of Results; Terfenadine

2010
In vivo probes of drug transport: commonly used probe drugs to assess function of intestinal P-glycoprotein (ABCB1) in humans.
    Handbook of experimental pharmacology, 2011, Issue:201

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Digoxin; Humans; Intestinal Mucosa; Molecular Probe Techniques; Molecular Probes; Propanolamines; Reproducibility of Results

2011
Drug-Drug Interactions of P-gp Substrates Unrelated to CYP Metabolism.
    Current drug metabolism, 2019, Volume: 20, Issue:2

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cytochrome P-450 Enzyme System; Dabigatran; Digoxin; Drug Interactions; Humans; Propanolamines; Terfenadine

2019

Trials

1 trial(s) available for talinolol and digoxin

ArticleYear
Oral bioavailability of digoxin is enhanced by talinolol: evidence for involvement of intestinal P-glycoprotein.
    Clinical pharmacology and therapeutics, 2000, Volume: 68, Issue:1

    Topics: Administration, Oral; Adrenergic beta-Antagonists; Adult; Area Under Curve; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Availability; Cardiotonic Agents; Chromatography, High Pressure Liquid; Cross-Over Studies; Digoxin; Drug Therapy, Combination; Female; Fluorescence Polarization Immunoassay; Half-Life; Humans; Infusions, Intravenous; Intestinal Absorption; Male; Propanolamines; Reference Values; Time Factors

2000

Other Studies

10 other study(ies) available for talinolol and digoxin

ArticleYear
pH-dependent bidirectional transport of weakly basic drugs across Caco-2 monolayers: implications for drug-drug interactions.
    Pharmaceutical research, 2003, Volume: 20, Issue:8

    Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Caco-2 Cells; Cell Membrane Permeability; Digoxin; Drug Interactions; Humans; Hydrogen-Ion Concentration; Intestinal Mucosa; Pharmaceutical Preparations; Pharmacokinetics

2003
Novel experimental parameters to quantify the modulation of absorptive and secretory transport of compounds by P-glycoprotein in cell culture models of intestinal epithelium.
    Pharmaceutical research, 2003, Volume: 20, Issue:8

    Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Blotting, Western; Cells, Cultured; Diffusion; Humans; Intestinal Absorption; Intestinal Mucosa; Models, Biological; Permeability; Pharmaceutical Preparations; Pharmacokinetics

2003
Predicting P-glycoprotein effects on oral absorption: correlation of transport in Caco-2 with drug pharmacokinetics in wild-type and mdr1a(-/-) mice in vivo.
    Pharmaceutical research, 2004, Volume: 21, Issue:5

    Topics: Administration, Oral; Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP-Binding Cassette Transporters; Biological Transport, Active; Caco-2 Cells; Cell Membrane Permeability; Humans; Intestinal Absorption; Mice; Mice, Knockout; Pharmacokinetics; Spectrometry, Mass, Electrospray Ionization

2004
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
    Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7

    Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding

2008
Physicochemical determinants of human renal clearance.
    Journal of medicinal chemistry, 2009, Aug-13, Volume: 52, Issue:15

    Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight

2009
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
    Journal of medicinal chemistry, 2010, Feb-11, Volume: 53, Issue:3

    Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations

2010
An alternative hypothesis to involvement of intestinal P-glycoprotein as the cause for digoxin oral bioavailability enhancement by talinolol.
    Clinical pharmacology and therapeutics, 2001, Volume: 69, Issue:1

    Topics: Administration, Oral; Adrenergic beta-Antagonists; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Availability; Cardiotonic Agents; Digoxin; Drug Interactions; Humans; Intestinal Absorption; Intestinal Mucosa; Propanolamines

2001
Modeling the kinetics of digoxin absorption: enhancement by P-glycoprotein inhibition.
    Journal of clinical pharmacology, 2012, Volume: 52, Issue:3

    Topics: Absorption; Anti-Arrhythmia Agents; Area Under Curve; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Availability; Cardiotonic Agents; Computer Simulation; Digoxin; Drug Interactions; Humans; Models, Biological; Normal Distribution; Propanolamines

2012
A simplified protocol employing elacridar in rodents: a screening model in drug discovery to assess P-gp mediated efflux at the blood brain barrier.
    Drug metabolism letters, 2012, Jun-01, Volume: 6, Issue:2

    Topics: Acridines; Animals; Area Under Curve; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Blood-Brain Barrier; Brain; Chromatography, Liquid; Cost-Benefit Analysis; Digoxin; Drug Design; Drug Interactions; Half-Life; Injections, Intravenous; Male; Mice; Propanolamines; Quinidine; Rats; Rats, Sprague-Dawley; Tandem Mass Spectrometry; Tetrahydroisoquinolines; Time Factors; Tissue Distribution

2012
Physiologically-Based Pharmacokinetic Modeling Approach to Predict Rifampin-Mediated Intestinal P-Glycoprotein Induction.
    CPT: pharmacometrics & systems pharmacology, 2019, Volume: 8, Issue:9

    Topics: Administration, Oral; ATP Binding Cassette Transporter, Subfamily B, Member 1; Dabigatran; Digoxin; Drug Interactions; Female; Gene Expression Regulation; Healthy Volunteers; Humans; Intestinal Mucosa; Male; Models, Biological; Propanolamines; Quinidine; Rifampin

2019